Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00583531 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis
A Phase 2 study, sponsored by Ocera Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00583531 is a Phase 2 study that was terminated before completion, run by Ocera Therapeutics. The registered enrollment target is 2 participants.
The verdict
NCT00583531, a Phase 2 study, was terminated before completion, sponsored by Ocera Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is an open-label pilot study in which all patients will receive AST-120 for 4 weeks. Patients will discontinue antibiotics at study entry. They may continue other previously prescribed treatments (e.g., probiotics and/or nutritional agents) at the discretion of the study doctor. The purpose of the study is to assess whether the investigational medication AST-120 will be a safe and effective treatment for the symptoms of pouchitis, a chronic inflammatory condition, in patients whose symptoms have not responded well to antibiotics. An initial group of 10 patients will be enrolled. If there are no serious side effects associated with the study drug and at least 3 of the 10 patients respond, a second group of 10 patients may be enrolled. Patients will have clinic visits at the start of the study and at week 4. Patients will be checked by phone on a weekly basis for symptom response, compliance and development of side effects. Endoscopies will be performed at the start of the study and at week 4 or early termination.
Interventions
- DRUG AST-120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00583531
The ClinicalTrials.gov registry entry for NCT00583531 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocera Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AST-120 is the first listed.
NCT00583531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00583531 about?
NCT00583531 is a clinical study titled "Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis". This is an open-label pilot study in which all patients will receive AST-120 for 4 weeks. Patients will discontinue antibiotics at study entry. They may continue other previously prescribed treatments (e.g., probiotics and/or nutritional agents) at the discretion of the study doctor. The purpose of ...
What is the current status of trial NCT00583531?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2007-03. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00583531?
The interventions under investigation include: AST-120 (DRUG).
Who is sponsoring clinical trial NCT00583531?
This trial is sponsored by Ocera Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.